Scalable suspension LVV production platforms for cell and gene therapy

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Scalable suspension LVV production platforms for cell and gene therapy

Lentiviral vector is the predominant delivery vehicle used for introducing genetic modifications into cell therapies such as CAR-T and HSC gene therapies. Fueled by recent clinical successes and landmark approvals, this field continues to experience unprecedented pipeline growth and investor interest along with a concommitant growth in demand for Lenti viral vector manufacturing. Traditional processes for Lenti manufacturing rely on lab-scale, open, manual processes that are predominantly adherent-based and difficult to scale up. There is a pressing need for industrialization of these production methods to meet market demand and to ensure successful commercialization of cell and gene therapies.

In this Webinar, Lonza CGT will focus on how we are tackling these challenges through development of an optimized, scalable suspension-based Lenti production platform using our proprietary HEK293T clonal cell line. We will also highlight some of the innovation and process improvements steps that have been implemented to support trailblazers of CGT to generate commercially viable therapies to from concept to patient.

Lentiviral vector market trends for CGT
Key manufacturing challenges of Lenti production
Solutions for developing commercially viable Lenti processes from concept to patient
Optimized LVV production using a proprietary HEK293T cell line and a scalable, suspension-based production platform

Suparna Sanyal

Head of Viral Vectors Commercial Development, Lonza Pharma & Biotec

Suparna Sanyal is an Innovation and Commercialization Manager at Lonza Cell and Gene Technologies where she works with their global business, R&D and operations teams to enable prioritization, strategic development and commercialization of their innovation portfolio. Suparna’s background is in Neuroscience and she earned her PhD from the University of Toronto in Neuropharmacology. She has over 15 years of broad pharmaceutical and CDMO experience driving innovation, drug discovery, product and service development for CNS, oncology and cell and gene therapy.

Michael Haller

Senior R&D Scientist, Viral Vector Process Development, Lonza Pharma & Biotec

Young Shin

R&D Principal Scientist, Cell & Gene Technologies, Lonza Pharma & Biotec

Young Shin works as a principal scientist in R&D at Lonza-Houston. His specific areas of focus include cell line development, vector design, upstream process optimization, downstream purification, and assay development to support large-scale production of the lentiviral vectors for cell and gene therapies. The goal of his work is to offer a ‘demonstrated process’ of lentivial vector production to the clients, which would help the clients to shorten the timeline and cost for their clinical studies. In this way, any early-stage pharmaceutical companies that do not have their own process can expedite their development cycle by working with Lonza. Young Shin studied polyomavirus assembly in his ph.D at the University of Missouri. His postdoctoral research at Harvard University and the University of Miami was focused on the human herpesvirus oncogenesis and HIV vaccine development using a non-human primate model system.